Science-Based Decision Confirms ZYN Nicotine Sachets Are a Better Alternative for Adult Smokers
The US Food and Drug Administration (FDA) has authorized the commercialization of ZYN nicotine sachets, a decision that the agency makes when, based on submitted scientific evidence, it determines that the sale of a product is “in accordance with the principles of protecting the public health”.
ZYN thus became the first and only product of its kind authorized by the FDA.
This authorization of all ZYN nicotine sachets currently sold in the US by Swedish Match, a company acquired by Philip Morris International in 2022, is an important step towards protecting public health, as it provides better alternatives for adult users of cigarettes and other traditional tobacco products.
After evaluating the evidence provided, the FDA concluded that ZYN brings more benefits to the health of the population than risks, especially when it comes to adult smokers who completely switch to ZYN nicotine sachets.
Tom Hyers, president of Swedish Match North America, said, “An estimated 45 million Americans regularly consume nicotine, and approximately 30 million of them smoke, the most harmful form of nicotine consumption. The FDA’s decision recognizes the role that ZYN can play in protecting public health by helping people quit cigarettes and other traditional tobacco products.”
You can find the FDA decision here.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company that is actively working to create a smoke-free future and is developing its portfolio to include products outside the tobacco and nicotine sectors in the long term. The company’s current product range consists mainly of cigarettes and smoke-free products. Since 2008, PMI has invested more than $12.5 billion in the development, scientific validation and commercialization of innovative smoke-free products for adult users who would otherwise continue to smoke, with the goal of eliminating cigarette sales altogether. This includes developing world-class scientific evaluation capabilities, particularly in the areas of preclinical systematic toxicology, clinical and behavioral research and post-marketing studies. In 2022, PMI acquired Swedish Match, a leader in oral nicotine products, and thus became a global leader in the smoke-free category, led by the IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has classified PMI’s versions of the IQOS device and cartridges, as well as Swedish Match’s snus products, as modified-risk tobacco products. As of June 30, 2024, PMI’s smoke-free products were available in 90 markets, and PMI estimates that 36.5 million adults worldwide were using PMI’s smoke-free products. Smoke-free products accounted for approximately 38% of PMI’s total net revenue in the first nine months of 2024. Building on a strong foundation and significant scientific expertise, PMI announced in February 2021 its ambition to enter the wellness and health care space with the goal of improving lives by delivering a seamless health experience. For more information, visit www.pmi.com and www.pmiscience.com